NCT02538510View on ClinicalTrials.gov

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 8, 2015

Primary Completion Date

September 28, 2019

Study Completion Date

September 15, 2023

Conditions
Head and Neck Squamous Cell CarcinomaRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Salivary Gland CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage III Major Salivary Gland CarcinomaStage III Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage III Nasopharyngeal CarcinomaStage IV Nasopharyngeal CarcinomaStage IVA Major Salivary Gland CarcinomaStage IVA Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVB Major Salivary Gland CarcinomaStage IVB Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVC Major Salivary Gland CarcinomaStage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Vorinostat

Given PO or via PEG

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02538510 - Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter